A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Imugene Limited
Seagen Inc.
Toray Industries, Inc
NGM Biopharmaceuticals, Inc
NGM Biopharmaceuticals, Inc
Celldex Therapeutics
Xencor, Inc.
M.D. Anderson Cancer Center